Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant

por Slatter, T L, Hung, N, Bowie, S, Campbell, H, Rubio, C, Speidel, D, Wilson, M, Baird, M, Royds, J A, Braithwaite, A W
Publicado 2015

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents

por Michaelis, M, Rothweiler, F, Agha, B, Barth, S, Voges, Y, Löschmann, N, von Deimling, A, Breitling, R, Wilhelm Doerr, H, Rödel, F, Speidel, D, Cinatl, J
Publicado 2012

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

por Michaelis, M, Rothweiler, F, Barth, S, Cinatl, J, van Rikxoort, M, Löschmann, N, Voges, Y, Breitling, R, von Deimling, A, Rödel, F, Weber, K, Fehse, B, Mack, E, Stiewe, T, Doerr, H W, Speidel, D, Cinatl, J
Publicado 2011